Publications by authors named "Alyssa Morimoto"

Claim this Profile
O
Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients.
Cary M Looney, Aaron Schroeder, Erica Tavares, Jay Garg, Thomas Schindler, Alyssa Morimoto

Transplant Direct· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
David Isenberg, Richard Furie, Nicholas S Jones, Pascal Guibord, Joshua Galanter, Alyssa M Morimoto

Arthritis Rheumatol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study).
Stanley Cohen, Katie Tuckwell, Tamiko R Katsumoto, Rui Zhao, Joshua Galanter, Alyssa M Morimoto

Arthritis Rheumatol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.
Robert R Redfield, Stanley C Jordan, Stephan Busque, Flavio Vincenti, E Steve Woodle, Alyssa Morimoto

Am J Transplant· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches.
Kelly M Loyet, Philip E Hass, Wendy N Sandoval, Ashley Morando, Peter Liu, Alyssa M Morimoto

Mol Pharm· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.
Ann E Herman, Leslie W Chinn, Shweta G Kotwal, Elaine R Murray, Rui Zhao, Alyssa M Morimoto

Clin Pharmacol Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commercial biomarker assays: friend and foe.
Saloumeh K Fischer, Montserrat Carrasco-Triguero, Kyu Hong, Jeremy Good, Teresa Davancaze, Alyssa Morimoto

Bioanalysis· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fit-for-purpose biomarker immunoassay qualification and validation: three case studies.
Kyra Cowan, Xiaoying Gao, Vaishali Parab, Trung Nguy, Lawren Wu, Alyssa Morimoto

Bioanalysis· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
Dinesh Khanna, Christopher P Denton, Angelika Jahreis, Jacob M van Laar, Tracy M Frech, Alyssa Morimoto

Lancet· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioanalytical challenges and improved detection of circulating levels of IL-13.
Fang Cai, Hans Hornauer, Kun Peng, Cheryl A Schofield, Heleen Scheerens, Alyssa M Morimoto

Bioanalysis· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity).
Lakshmi Amaravadi, An Song, Heather Myler, Theingi Thway, Susan Kirshner, Alyssa Morimoto

Bioanalysis· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy.
Kha N Le, Leonid Gibiansky, Jeremy Good, Teresa Davancaze, Menno van Lookeren Campagne, Alyssa Morimoto

J Pharmacol Exp Ther· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development.
Masood U Khan, Ronald R Bowsher, Mark Cameron, Viswanath Devanarayan, Steve Keller, Alyssa Morimoto

Bioanalysis· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE.
William P Kennedy, Romeo Maciuca, Kristen Wolslegel, Wei Tew, Alexander R Abbas, Alyssa Morimoto

Lupus Sci Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration.
Kelly M Loyet, Jeremy Good, Teresa Davancaze, Lizette Sturgeon, Xiangdan Wang, Alyssa Morimoto

J Pharmacol Exp Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of Pharmaceutical Scientists.
Li Xue, Michele Fiscella, Manoj Rajadhyaksha, Jaya Goyal, Claire Holland, Alyssa Morimoto

AAPS J· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
Jacqueline M McBride, Jenny Jiang, Alexander R Abbas, Alyssa Morimoto, Jing Li

Arthritis Rheum· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus.
Alyssa M Morimoto, Donna Thibault Flesher, Jihong Yang, Kristen Wolslegel, Xiangdan Wang

Arthritis Rheum· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor.
Alyssa M Morimoto, Nguyen Tan, Kristina West, Grant McArthur, Guy C Toner

Oncogene· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Maurizio Zangari, Elias Anaissie, Alison Stopeck, Alyssa Morimoto, Nguyen Tan

Clin Cancer Res· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis